Intrexon | XON - Debt


Intrexon reported $0 in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Amgen USD 54.59B 1.62B Sep/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Incyte USD 40.41M 855K Dec/2025
Intrexon USD 0 13.82M Jun/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
MannKind USD 119.91M 73.09M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Thermo Fisher Scientific USD 35.68B 451M Sep/2025
Veracyte USD 40.45M 10.19M Sep/2025
Xencor USD 69.27M 1.34M Sep/2025